Sangeetha Sundaramoorthy has submitted to the Exchange a copy of Disclosures under Regulation 10(6)-Report to stock Exchange in respect of any acquisition made in reliance upon exemption provided for in regulation 10 of SEBI (SAST) Regulations, 2011.
LOTUSEYE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Promoter Sangeetha Sundaramoorthy has acquired 11,42,900 shares of Lotus Eye Hospital and Institute Limited at Rs 70 per share from fellow promoter Kavetha Sundaramoorthy, pursuant to a share purchase agreement dated 2nd June 2025. The transaction was completed on 18th September 2025 and represents 5.4956% of the company's diluted share capital. Post-transaction, Sangeetha's holding rises from 22.61% (47,02,801 shares) to 28.11% (58,45,701 shares), while Kavetha's holding falls from 15.11% (31,42,464 shares) to 9.61% (19,99,564 shares). The acquirer has claimed exemption from making an open offer under Regulation 10(1)(a)(i) of SEBI (SAST) Regulations, 2011, with prior intimation made on 9th September 2025.
This is a reshuffling of shares between two promoters and does not change the total promoter holding in the company. No impact on retail shareholders or open market price is expected, as the deal was a private inter-promoter transfer at an agreed price.